Skip to main content

William J. Bussiere, Jr.

Associate

[email protected]

+1.617.348.3059

Share:

Will focuses his practice on corporate counseling and fundamental transactions for emerging companies. He has represented public and private companies in all stages of their life cycles, including company formation, venture capital and debt financing, mergers and acquisitions, capital markets transactions, and securities law compliance. He also advises companies on governance matters, commercial contracts and equity compensation.

Will’s clients are active in a wide range of industries from life sciences and technology services to consumer retail and private investments. He is active in Mintz’s Life Science Practice, with clients across the industry in biotechnology, medical devices and pharmaceuticals. Will is also a part of Mintz’s Sports & Entertainment Practice, with a focus on business contracts and charitable foundations for professional athletes. 

Before joining Mintz, Will advised closely-held businesses and practiced in the areas of real estate financing and transactions, affordable housing development and finance, and general litigation. He was also a legal fellow to the general counsel of the Boston Redevelopment Authority (now known as the Boston Planning & Development Agency), where he focused on large project review, regulatory compliance, municipal asset management, and tax agreements.

Experience

  • Cheetah Medical, a provider of noninvasive hemodynamic monitoring devices, in connection with its sale to Baxter International Inc. (NYSE:BAX)
  • Aura Biosciences in its $30M and $40M financings to advance the clinical development of its Ocular Melanoma treatment
  • Synlogic (NASDAQ:SYBX) in its IPO by way of a reverse merger with Mirna Therapeutics, Inc. and its $42M, $40M, $30M and $42M financings to develop “living therapeutics”
  • Endotronix in its $37M Series C and $40M Series D financings to develop a medical device system targeting heart failure management
  • NBD Nanotechnologies in Series A and Series B financings to develop repellent nanocoatings for consumer products
  • John Hancock Financial Network in its sale of Signator Investors to Advisor Group
  • Naurex in its sale to Allergan for upfront payment of $560M and additional milestones to commercialize an antidepressant therapy
  • Pedro Martinez Foundation in its U.S. relaunch and public charity conversion
     
Read less

viewpoints

Founders choosing a structure for their business are often drawn to the limited liability company, or LLC, for its overall flexibility in both taxation and governance matters. And founders seeking access to early capital, not to mention seed investors themselves, are often drawn to the convertible note as a simple, less expensive means to raise funds. But LLCs and convertible debt don’t always mix.
Read more
Read less

News & Press

Press Release Thumbnail

BOSTON – Mintz announced today that it advised Hopewell Therapeutics, a biotechnology company with a differentiated lipid nanoparticle platform harnessing unique ionizable lipid chemistry, in its Seed Financing of up to $25 million. The funds will enable Hopewell to advance the development of genomic medicines based on its differentiated tissue-targeted Lipid Nanoparticle (ttLNP) platform through both internal pipeline programs and external partnerships.

Press Release Thumbnail

BOSTON – Mintz is pleased to announce that Associates William J. Bussiere, Jr., Natalie C. Groot,  and Kevin C. Mortimer have been selected to join Greater Boston Chamber of Commerce’s 2023 Boston’s Future Leaders Program.

Press Release Thumbnail

Mintz represented CXL Ophthalmics (CXLO), a clinical-stage company developing a minimally-invasive treatment for keratoconus, in a $32 million Series A round of fundraising.

Press Release Thumbnail
Mintz advised Cardurion Pharmaceuticals, Inc., a biotechnology company developing novel therapeutics to treat heart failure and other cardiovascular diseases, in a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity that will enable the Boston-based company to expand its drug discovery programs.
Read less